| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | 0.014 | 0.9 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.015 | 0.9 |